Generic Medicine Info
Indications and Dosage
Otitis media, Respiratory tract infections, Skin infections, Soft tissue infections, Urinary tract infections
Adult: 250-500 mg 8 hrly. Max: 4 g daily.
Child: >1 mth 20-40 mg/kg daily in 2 or 3 divided doses. Max: 0.75-1.5 g daily.
May be taken with or without food.
Add the amount of water specified on the container in 2 portions to provide a susp containing 125, 187, 250 or 375 mg per 5 mL. Shake the bottle after each addition.
Hypersensitivity to cefaclor or to other cephalosporins.
Special Precautions
Hypersensitivity to penicillins. History of GI disease. Renal impairment. Pregnancy and lactation.
Adverse Reactions
GI effects (e.g. diarrhoea, nausea, vomiting), headache, rash. Rarely, serum sickness-like reactions consisting of erythema multiforme or maculopapular pruritic rash or urticaria accompanied by arthritis, arthralgia, irritability and fever.
Potentially Fatal: Severe hypersensitivity reactions (e.g. Stevens-Johnson syndrome, toxic epidermal necrolysis and anaphylaxis), pseudomembranous colitis.
Monitoring Parameters
Monitor renal function. Observe for signs of anaphylaxis during 1st dose.
Symptoms: Nausea, vomiting, epigastric distress, diarrhoea. Management: Supportive treatment.
Drug Interactions
May enhance the nephrotoxic effect of aminoglycosides. May diminish the therapeutic effect of BCG, typhoid vaccine and Na picosulfate. Concomitant use w/ warfarin may increase prothrombin time. Probenecid inhibits renal excretion of cefaclor.
Food Interaction
Food may delay the rate but does not affect the extent of absorption.
Lab Interference
False-positive reaction in urinary glucose test using Benedict's or Fehling's soln or copper sulfate test tablets. Positive direct Coombs' test.
Description: Cefaclor inhibits bacterial cell wall synthesis by binding to 1 or more of the penicillin-binding proteins (PBPs) which in turn inhibit the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
Absorption: Well absorbed from the GI tract. Food may delay the rate but does not affect the extent of absorption. Time to peak plasma concentration: 0.5-1 hr.
Distribution: Widely distributed. Crosses the placenta and enters breast milk. Plasma protein binding: Approx 25%.
Excretion: Via urine (up to 85%, as unchanged drug). Plasma half-life: 0.5-1 hr.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Cefaclor, CID=51039, https://pubchem.ncbi.nlm.nih.gov/compound/Cefaclor (accessed on Jan. 21, 2020)

Store between 20-25°C. Protect from moisture. Reconstituted powd for susp: Store between 2-8°C.
MIMS Class
ATC Classification
J01DC04 - cefaclor ; Belongs to the class of second-generation cephalosporins. Used in the systemic treatment of infections.
Anon. Cefaclor. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 10/10/2014.

Buckingham R (ed). Cefaclor. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 10/10/2014.

Cefaclor Capsule (Carlsbad Technology, Inc). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 10/10/2014.

Cefaclor Suspension (Carlsbad Technology Inc). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 10/10/2014.

McEvoy GK, Snow EK, Miller J et al (eds). Cefaclor. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 10/10/2014.

Disclaimer: This information is independently developed by MIMS based on Cefaclor from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by MIMS.com
  • Cloracef
  • Soclor
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in